09 March 2001
Ann Transplant 2001; 6(1): 5-8 :: ID: 497563
The evidence that lipid disorders in patients following renal transplantation playa major role in the pathogenesis of atherosclerosis and chronic renal allograft rejection is circumstantial. The high rate of clinical vascular disease and cardiovascular complications in renal transplant recipients, the high prevalence of an atherogenic dyslipidemia and the evidence from the statin regression trials in the general population suggest that lipid lowering treatment is beneficial in patients after renal transplantation. In addition, animal models and observational studies in patients have demonstrated correlations between plasma lipid levels and both acute and chronic rejection. Animal transplant models and clinical trials in heart transplant patients also suggest that statin treatment decreases the incidence of chronic rejection. However, the mechanisms behind this protective effect remain unsolved and no conclusive data exist proving that statins directly inhibit the development of chronic rejection. However, sufficient evidence exists to consider the use of these agents in the posttransplant setting for their possible effects on cardiovascular complications.
Keywords: Cholesterol, trigliceride, Graft Rejection, immunosuppresion
06 Feb 2024 : Case reportSuccessful Sequential Liver and Isolated Intestine Transplantation for Mitochondrial Neurogastrointestinal ...
Ann Transplant In Press; DOI: 10.12659/AOT.941881
12 Feb 2024 : Original articleNo Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...
Ann Transplant In Press; DOI: 10.12659/AOT.942767
Most Viewed Current Articles
05 Apr 2022 : Original articleImpact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original articleRisk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original articleLong-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...
Ann Transplant 2022; 27:e937988